PWAM
AKBA icon

Private Wealth Asset Management’s Akebia Therapeutics AKBA Stock Holding History

Private Wealth Asset Management’s Portfolio AKBA Stock Details AKBA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$570 Hold
500
– – ﹤0.01% 903
2026
Q1 		$695 Buy
+500
New +$687 ﹤0.01% 893

Other funds holding AKBA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Private Wealth Asset Management's AKBA Position: Q2 2026 in Review

Private Wealth Asset Management held its Akebia Therapeutics (AKBA) position steady in Q2 2026 at 500 shares worth $570. The position accounts for ﹤0.01% of the portfolio, ranked #903.

Private Wealth Asset Management first reported a position in AKBA in Q1 2026 and has held it in 2 quarters since. The position peaked at $695 in Q1 2026. 171 funds tracked by Wall St. Rank hold AKBA as of Q2 2026.

  • Private Wealth Asset Management held 500 shares of Akebia Therapeutics worth $570 as of Q2 2026.
  • Private Wealth Asset Management left its Akebia Therapeutics share count unchanged in Q2 2026.
  • Akebia Therapeutics made up ﹤0.01% of Private Wealth Asset Management's portfolio in Q2 2026, its #903 holding.
  • Private Wealth Asset Management first reported a position in Akebia Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • Private Wealth Asset Management's Akebia Therapeutics position peaked at $695 in Q1 2026.
  • 171 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q2 2026.

Based on Private Wealth Asset Management's 13F filing for Q2 2026, filed 11 Aug 2026.